Panelists discuss how emerging data on chimeric antigen receptor T-cell therapies ciltacabtagene autoleucel and idecabtagene vicleucel for earlier treatment lines in relapsed/refractory multiple myeloma influence institutional decision-making factors for their implementation.
Health Canada approved fruquintinib for select patients with metastatic colorectal cancer.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Single-agent adjuvant chemotherapy did not improve overall survival when compared to no adjuvant chemotherapy.
The FDA has granted a breakthrough device designation to the DCISionRT test for patients with breast cancer with ductal carcinoma in situ.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Frontline dostarlimab plus chemotherapy has been approved in the EU for all adult patients with primary advanced or recurrent endometrial cancer.
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Blood and Marrow Transplant Clinical Trials Network Clinical Program Manager Mykala Heuer, BSN, RN, outlines highlights in the agenda, including discussions on operations, empowering coordinators,…
Andrea Roman, PharmD, BCOP, US Oncology Network and McKesson, discussed the integration of clinical pharmacists into community oncology practices.
A real-world study found blinatumomab plus ponatinib as more likely to be effective if used in earlier lines of therapy.
